Alterome Therapeutics, Inc.
Clinical trials sponsored by Alterome Therapeutics, Inc., explained in plain language.
-
New drug targets rare gene mutation in Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests an experimental drug called ALTA2618 in about 110 adults whose advanced solid tumors (including breast and endometrial cancers) have a specific AKT1 E17K gene mutation. The main goals are to check the drug's safety and find the right dose. Participant…
Phase: PHASE1 • Sponsor: Alterome Therapeutics, Inc. • Aim: Disease control
Last updated May 16, 2026 22:32 UTC
-
New drug targets KRAS-mutant cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called ALTA3263 in adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS gene mutation. The main goals are to check safety and find the right dose. About 188 people who have tried other tr…
Phase: PHASE1 • Sponsor: Alterome Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:49 UTC